Enanta Pharmaceuticals
ENTA
ENTA
105 hedge funds and large institutions have $199M invested in Enanta Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 40 increasing their positions, 42 reducing their positions, and 42 closing their positions.
New
Increased
Maintained
Reduced
Closed
more ownership
Funds ownership: →
more funds holding in top 10
Funds holding in top 10: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less capital invested
Capital invested by funds: $ → $
20% less funds holding
Funds holding: 132 → 105 (-27)
64% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 42
65% less call options, than puts
Call options by funds: $18K | Put options by funds: $51K
Holders
105
Holding in Top 10
1
Calls
$18K
Puts
$51K
Top Buyers
| 1 | +$16.8M | |
| 2 | +$2.82M | |
| 3 | +$2.77M | |
| 4 |
D.E. Shaw & Co
New York
|
+$2.61M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$2.03M |
Top Sellers
| 1 | -$11.6M | |
| 2 | -$5.82M | |
| 3 | -$2.43M | |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.22M |
| 5 |
HF
HRT Financial
New York
|
-$1.15M |